Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with ...
The FDA has approved pirtobrutinib (Jaypirca) monotherapy as a treatment for adults with previously untreated chronic ...
In a conversation with CancerNetwork ® at the 23rd Annual International Myeloma Society (IMS) Meeting & Exposition, Jeffrey V. Matous, MD, discussed the feasibility of standardiz ...
William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.
Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue ...
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across ...
Hall, MD, professor and chair of radiation oncology at the Medical College of Wisconsin and medical director of Froedtert ...
Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma. In an interview with CancerNetwork® at the 2026 American Society for ...
Intensity-modulated proton therapy (IMPT) allows radiation oncologists to limit the dose to organs surrounding the prostate. That property may be particularly relevant for patients with prostate ...
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence ...
Most of the KRAS inhibitors that have produced clinical data in biliary tract cancer so far target KRAS G12C, a mutation found in only a minority of patients with KRAS-mutant dise ...
Agarwal presented the TALAPRO-3 results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Agarwal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results